1
|
Willcox TM, Speer RW, Schlinkert RT and
Sarr MG: Hemangioma of the spleen: Presentation, diagnosis, and
management. J Gastrointest Surg. 4:611–613. 2000. View Article : Google Scholar
|
2
|
Husni EA: The clinical course of splenic
hemangioma with emphasis on spontaneous rupture. Arch Surg.
83:681–688. 1961. View Article : Google Scholar : PubMed/NCBI
|
3
|
Arber DA, Strickler JG, Chen YY and Weiss
LM: Splenic vascular tumors: A histologic, immunophenotypic, and
virologic study. Am J Surg Pathol. 21:827–835. 1997. View Article : Google Scholar : PubMed/NCBI
|
4
|
Kutok JL and Fletcher CD: Splenic vascular
tumors. Semin Diagn Pathol. 20:128–139. 2003. View Article : Google Scholar : PubMed/NCBI
|
5
|
Abbott RM, Levy AD, Aguilera NS, Gorospe L
and Thompson WM: From the archives of the AFIP: primary vascular
neoplasms of the spleen: radiologic-pathologic correlation.
Radiographics. 24:1137–1163. 2004. View Article : Google Scholar : PubMed/NCBI
|
6
|
Halgrimson CG, Rustad DG and Zeligman BE:
Calcified hemangioma of the spleen. JAMA. 252:2959–2960. 1984.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Kaplan J and McIntosh GS: Spontaneous
rupture of a splenic vascular malformation. A report of three cases
and review of the literature. J R Coll Surg Edinb. 32:346–347.
1987.PubMed/NCBI
|
8
|
Rao RC, Ghose R, Sawhney S and Berry M:
Hemangioma of spleen with spontaneous, extra-peritoneal rupture,
with associated splenic tuberculosis - an unusual presentation.
Australas Radiol. 37:100–101. 1993. View Article : Google Scholar : PubMed/NCBI
|
9
|
Pachl M, Elmalik K, Cohen M, Kamupira S,
Walker J and Murthi G: Ruptured splenic cavernous hemangioma in a
neonate. J Pediatr Surg. 43:407–409. 2008. View Article : Google Scholar : PubMed/NCBI
|
10
|
Carta G, D'Alfonso A, Nallbani A, Palermo
P, Franchi V and Patacchiola F: Spontaneous rupture of splenic
hemangioma in puerperium. Clin Exp Obstet Gynecol. 39:407–408.
2012.PubMed/NCBI
|
11
|
Kang LY, Huang FD and Liu YY: Blunt
abdominal injury with rupture of giant hepatic cavernous hemangioma
and laceration of the spleen. Hepatobiliary Pancreat Dis Int.
14:109–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
12
|
Hoeger PH, Helmke K and Winkler K: Chronic
consumption coagulopathy due to an occult splenic haemangioma:
Kasabach-Merritt syndrome. Eur J Pediatr. 154:365–368. 1995.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Schaffer LG, Slovak ML and Campbell LJ:
ISCN 2009: an International System for Human Cytogenetic
Nomenclature. Karger; Basel: 2009
|
14
|
Kim D, Pertea G, Trapnell C, Pimentel H,
Kelley R and Salzberg SL: TopHat2: Accurate alignment of
transcriptomes in the presence of insertions, deletions and gene
fusions. Genome Biol. 14:R362013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Kim D and Salzberg SL: TopHat-Fusion: An
algorithm for discovery of novel fusion transcripts. Genome Biol.
12:R722011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Panagopoulos I, Gorunova L, Bjerkehagen B
and Heim S: Fusion of the genes EWSR1 and PBX3 in retroperitoneal
leiomyoma with t(9;22)(q33;q12). PLoS One. 10:e01242882015.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Kimura K, Wakamatsu A, Suzuki Y, Ota T,
Nishikawa T, Yamashita R, Yamamoto J, Sekine M, Tsuritani K,
Wakaguri H, et al: Diversification of transcriptional modulation:
Large-scale identification and characterization of putative
alternative promoters of human genes. Genome Res. 16:55–65. 2006.
View Article : Google Scholar :
|
18
|
Li JY, Daniels G, Wang J and Zhang X:
TBL1XR1 in physiological and pathological states. Am J Clin Exp
Urol. 3:13–23. 2015.PubMed/NCBI
|
19
|
Xu C and Min J: Structure and function of
WD40 domain proteins. Protein Cell. 2:202–214. 2011. View Article : Google Scholar : PubMed/NCBI
|
20
|
Li D and Roberts R: WD-repeat proteins:
Structure characteristics, biological function, and their
involvement in human diseases. Cell Mol Life Sci. 58:2085–2097.
2001. View Article : Google Scholar
|
21
|
Neer EJ, Schmidt CJ, Nambudripad R and
Smith TF: The ancient regulatory-protein family of WD-repeat
proteins. Nature. 371:297–300. 1994. View Article : Google Scholar : PubMed/NCBI
|
22
|
Nakamura T, Tateishi K, Niwa T, Matsushita
Y, Tamura K, Kinoshita M, Tanaka K, Fukushima S, Takami H, Arita H,
et al: Recurrent mutations of CD79B and MYD88 are the hallmark of
primary central nervous system lymphomas. Neuropathol Appl
Neurobiol. Jun 25–2015.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
23
|
Gonzalez-Aguilar A, Idbaih A, Boisselier
B, Habbita N, Rossetto M, Laurenge A, Bruno A, Jouvet A, Polivka M,
Adam C, et al: Recurrent mutations of MYD88 and TBL1XR1 in primary
central nervous system lymphomas. Clin Cancer Res. 18:5203–5211.
2012. View Article : Google Scholar : PubMed/NCBI
|
24
|
Parker H, An Q, Barber K, Case M, Davies
T, Konn Z, Stewart A, Wright S, Griffiths M, Ross FM, et al: The
complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic
leukemia highlights a recurrent deletion of TBL1XR1. Genes
Chromosomes Cancer. 47:1118–1125. 2008. View Article : Google Scholar : PubMed/NCBI
|
25
|
Scott DW, Mungall KL, Ben-Neriah S, Rogic
S, Morin RD, Slack GW, Tan KL, Chan FC, Lim RS, Connors JM, et al:
TBL1XR1/TP63: A novel recurrent gene fusion in B-cell non-Hodgkin
lymphoma. Blood. 119:4949–4952. 2012. View Article : Google Scholar : PubMed/NCBI
|
26
|
Vasmatzis G, Johnson SH, Knudson RA,
Ketterling RP, Braggio E, Fonseca R, Viswanatha DS, Law ME, Kip NS,
Ozsan N, et al: Genome-wide analysis reveals recurrent structural
abnormalities of TP63 and other p53-related genes in peripheral
T-cell lymphomas. Blood. 120:2280–2289. 2012. View Article : Google Scholar : PubMed/NCBI
|
27
|
Chen Y, Li S, Zhou C, Li C, Ru K, Rao Q,
Xing H, Tian Z, Tang K, Mi Y, et al: TBLR1 fuses to retinoid acid
receptor α in a variant t(3;17)(q26;q21) translocation of acute
promyelocytic leukemia. Blood. 124:936–945. 2014. View Article : Google Scholar : PubMed/NCBI
|
28
|
Hahn Y, Bera TK, Gehlhaus K, Kirsch IR,
Pastan IH and Lee B: Finding fusion genes resulting from chromosome
rearrangement by analyzing the expressed sequence databases. Proc
Natl Acad Sci USA. 101:13257–13261. 2004. View Article : Google Scholar : PubMed/NCBI
|
29
|
Stransky N, Cerami E, Schalm S, Kim JL and
Lengauer C: The landscape of kinase fusions in cancer. Nat Commun.
5:48462014. View Article : Google Scholar : PubMed/NCBI
|
30
|
Benecke AG and Eilebrecht S, Benecke A and
Eilebrecht S: RNA-mediated regulation of HMGA1 function.
Biomolecules. 5:943–957. 2015. View Article : Google Scholar : PubMed/NCBI
|
31
|
Reeves R and Beckerbauer L: HMGI/Y
proteins: Flexible regulators of transcription and chromatin
structure. Biochim Biophys Acta. 1519:13–29. 2001. View Article : Google Scholar : PubMed/NCBI
|
32
|
Resar LM: The high mobility group A1 gene:
Transforming inflammatory signals into cancer? Cancer Res.
70:436–439. 2010. View Article : Google Scholar : PubMed/NCBI
|
33
|
Zhang Z, Wang Q, Chen F and Liu J:
Elevated expression of HMGA1 correlates with the malignant status
and prognosis of non-small cell lung cancer. Tumour Biol.
36:1213–1219. 2015. View Article : Google Scholar
|
34
|
Huang R, Huang D, Dai W and Yang F:
Overexpression of HMGA1 correlates with the malignant status and
prognosis of breast cancer. Mol Cell Biochem. 404:251–257. 2015.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Liau SS, Rocha F, Matros E, Redston M and
Whang E: High mobility group AT-hook 1 (HMGA1) is an independent
prognostic factor and novel therapeutic target in pancreatic
adenocarcinoma. Cancer. 113:302–314. 2008. View Article : Google Scholar : PubMed/NCBI
|
36
|
Wood LJ, Mukherjee M, Dolde CE, Xu Y,
Maher JF, Bunton TE, Williams JB and Resar LM: HMG-I/Y, a new c-Myc
target gene and potential oncogene. Mol Cell Biol. 20:5490–5502.
2000. View Article : Google Scholar : PubMed/NCBI
|
37
|
Dhar A, Hu J, Reeves R, Resar LM and
Colburn NH: Dominant-negative c-Jun (TAM67) target genes: HMGA1 is
required for tumor promoter-induced transformation. Oncogene.
23:4466–4476. 2004. View Article : Google Scholar : PubMed/NCBI
|
38
|
Zhao XX, Yuan QZ, Mu DP, Sun DW, Bo QA,
Pan GZ, Li GQ, Cui T, Ding PP, You FP, et al: MicroRNA-26a inhibits
proliferation by targeting high mobility group AT-hook 1 in breast
cancer. Int J Clin Exp Pathol. 8:368–373. 2015.PubMed/NCBI
|
39
|
Liu K, Zhang C, Li T, Ding Y, Tu T, Zhou
F, Qi W, Chen H and Sun X: Let-7a inhibits growth and migration of
breast cancer cells by targeting HMGA1. Int J Oncol. 46:2526–2534.
2015.PubMed/NCBI
|
40
|
Xu G, Wang J, Jia Y, Shen F, Han W and
Kang Y: MiR-142-3p functions as a potential tumor suppressor in
human osteosarcoma by targeting HMGA1. Cell Physiol Biochem.
33:1329–1339. 2014. View Article : Google Scholar : PubMed/NCBI
|
41
|
Bush BM, Brock AT, Deng JA, Nelson RA Jr
and Sumter TF: The Wnt/β-catenin/T-cell factor 4 pathway
up-regulates high-mobility group A1 expression in colon cancer.
Cell Biochem Funct. 31:228–236. 2013. View Article : Google Scholar :
|
42
|
Kazmierczak B, Bol S, Wanschura S,
Bartnitzke S and Bullerdiek J: PAC clone containing the HMGI(Y)
gene spans the breakpoint of a 6p21 translocation in a uterine
leiomyoma cell line. Genes Chromosomes Cancer. 17:191–193. 1996.
View Article : Google Scholar : PubMed/NCBI
|
43
|
Kazmierczak B, Wanschura S, Rommel B,
Bartnitzke S and Bullerdiek J: Ten pulmonary chondroid hamartomas
with chromosome 6p21 breakpoints within the HMG-I(Y) gene or its
immediate surroundings. J Natl Cancer Inst. 88:1234–1236. 1996.
View Article : Google Scholar : PubMed/NCBI
|
44
|
Dal Cin P, Wanschura S, Christiaens MR,
Van den Berghe I, Moerman P, Polito P, Kazmierczak B, Bullerdiek J
and Van den Berghe H: Hamartoma of the breast with involvement of
6p21 and rearrangement of HMGIY. Genes Chromosomes Cancer.
20:90–92. 1997. View Article : Google Scholar : PubMed/NCBI
|
45
|
Williams AJ, Powell WL, Collins T and
Morton CC: HMGI(Y) expression in human uterine leiomyomata.
Involvement of another high-mobility group architectural factor in
a benign neoplasm. Am J Pathol. 150:911–918. 1997.PubMed/NCBI
|
46
|
Xiao S, Lux ML, Reeves R, Hudson TJ and
Fletcher JA: HMGI(Y) activation by chromosome 6p21 rearrangements
in multilineage mesenchymal cells from pulmonary hamartoma. Am J
Pathol. 150:901–910. 1997.PubMed/NCBI
|
47
|
Kazmierczak B, Dal Cin P, Wanschura S,
Borrmann L, Fusco A, Van den Berghe H and Bullerdiek J: HMGIY is
the target of 6p21.3 rearrangements in various benign mesenchymal
tumors. Genes Chromosomes Cancer. 23:279–285. 1998. View Article : Google Scholar : PubMed/NCBI
|
48
|
Kazmierczak B, Meyer-Bolte K, Tran KH,
Wöckel W, Breightman I, Rosigkeit J, Bartnitzke S and Bullerdiek J:
A high frequency of tumors with rearrangements of genes of the
HMGI(Y) family in a series of 191 pulmonary chondroid hamartomas.
Genes Chromosomes Cancer. 26:125–133. 1999. View Article : Google Scholar : PubMed/NCBI
|
49
|
Tallini G, Vanni R, Manfioletti G,
Kazmierczak B, Faa G, Pauwels P, Bullerdiek J, Giancotti V, Van Den
Berghe H and Dal Cin P: HMGI-C and HMGI(Y) immunoreactivity
correlates with cytogenetic abnormalities in lipomas, pulmonary
chondroid hamartomas, endometrial polyps, and uterine leiomyomas
and is compatible with rearrangement of the HMGI-C and HMGI(Y)
genes. Lab Invest. 80:359–369. 2000. View Article : Google Scholar : PubMed/NCBI
|
50
|
Medeiros F, Araujo AR, Erickson-Johnson
MR, Kashyap PC, Dal Cin P, Nucci M, Wang X, Bell DA and Oliveira
AM: HMGA1 and HMGA2 rearrangements in mass-forming endometriosis.
Genes Chromosomes Cancer. 49:630–634. 2010.PubMed/NCBI
|
51
|
Nezhad MH, Drieschner N, Helms S, Meyer A,
Tadayyon M, Klemke M, Belge G, Bartnitzke S, Burchardt K, Frantzen
C, et al: 6p21 rearrangements in uterine leiomyomas targeting
HMGA1. Cancer Genet Cytogenet. 203:247–252. 2010. View Article : Google Scholar : PubMed/NCBI
|
52
|
Wang X, Zamolyi RQ, Zhang H, Pannain VL,
Medeiros F, Erickson-Johnson M, Jenkins RB and Oliveira AM: Fusion
of HMGA1 to the LPP/TPRG1 intergenic region in a lipoma identified
by mapping paraffin-embedded tissues. Cancer Genet Cytogenet.
196:64–67. 2010. View Article : Google Scholar
|
53
|
Gerlitz G, Darhin E, Giorgio G, Franco B
and Reiner O: Novel functional features of the Lis-H domain: Role
in protein dimerization, half-life and cellular localization. Cell
Cycle. 4:1632–1640. 2005. View Article : Google Scholar : PubMed/NCBI
|
54
|
Mateja A, Cierpicki T, Paduch M, Derewenda
ZS and Otlewski J: The dimerization mechanism of LIS1 and its
implication for proteins containing the LisH motif. J Mol Biol.
357:621–631. 2006. View Article : Google Scholar : PubMed/NCBI
|